504 related articles for article (PubMed ID: 38148756)
1. Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight.
Chakraborty S; Verma A; Garg R; Singh J; Verma H
Clin Med Insights Endocrinol Diabetes; 2023; 16():11795514231220780. PubMed ID: 38148756
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Dysregulation and Its Multifaceted Impact on Cardiovascular Autonomic Control in Type 2 Diabetes Mellitus: Insights From Comprehensive Assessment.
Kanagala A; J M H
Cureus; 2024 May; 16(5):e59776. PubMed ID: 38846218
[TBL] [Abstract][Full Text] [Related]
5. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
[TBL] [Abstract][Full Text] [Related]
6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Syndrome in Type 2 Diabetes Mellitus Patients: Prevalence, Risk Factors, and Associated Microvascular Complications.
Asghar S; Asghar S; Shahid S; Fatima M; Bukhari SMH; Nadeem Siddiqui S
Cureus; 2023 May; 15(5):e39076. PubMed ID: 37323312
[TBL] [Abstract][Full Text] [Related]
8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
9. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
10. The possible correlation between serum GRB2 levels and carotid atherosclerosis in patients with type 2 diabetes mellitus.
Dong Y; Liu J; Ma J; Quan J; Bao Y; Cui Y
Front Endocrinol (Lausanne); 2022; 13():963191. PubMed ID: 36176460
[TBL] [Abstract][Full Text] [Related]
11. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
12. Effect of GLP-1 based therapies on diabetic dyslipidemia.
Patel VJ; Joharapurkar AA; Shah GB; Jain MR
Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
[TBL] [Abstract][Full Text] [Related]
13. Comorbid overweight/obesity and chronic pancreatitis exacerbate the dyslipidemia progression in type 2 diabetic patients.
Marushchak M; Kozak K; Krynytska I
Endocr Regul; 2022 Jul; 56(3):168-177. PubMed ID: 35843717
[No Abstract] [Full Text] [Related]
14. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
15. Differences in cardiometabolic risk profiles between Chinese and Finnish older adults with glucose impairment and central obesity.
Le S; Zhang Y; Voutilainen A; Tan X; Laukkanen J; Wang C; Cheng S
J Endocrinol Invest; 2022 Jul; 45(7):1427-1437. PubMed ID: 35325446
[TBL] [Abstract][Full Text] [Related]
16. Small dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization.
Zhang F; Zhang Y; Zhang J; Wang X; Li Y; Wang W
PLoS One; 2024; 19(2):e0298070. PubMed ID: 38330008
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].
Vanuzzo D; Pilotto L; Mirolo R; Pirelli S
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):6S-17S. PubMed ID: 18773746
[TBL] [Abstract][Full Text] [Related]
18. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammationâmediating treatment options (Review).
Varra FN; Varras M; Varra VK; Theodosis-Nobelos P
Mol Med Rep; 2024 Jun; 29(6):. PubMed ID: 38606791
[TBL] [Abstract][Full Text] [Related]
19. TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION RATIO IDENTIFIES ACCENTUATED CARDIOMETABOLIC RISK.
Armato J; Reaven G; Ruby R
Endocr Pract; 2015 May; 21(5):495-500. PubMed ID: 25667373
[TBL] [Abstract][Full Text] [Related]
20. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
Murakami T; Inagaki N; Kondoh H
Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
